<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878293</url>
  </required_header>
  <id_info>
    <org_study_id>449723</org_study_id>
    <nct_id>NCT00878293</nct_id>
  </id_info>
  <brief_title>Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic</brief_title>
  <official_title>A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether the new centrally active analgesic and MS
      Continus® are effective in the treatment of painful diabetic polyneuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daily pain intensity</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1, 40 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2, 120 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS Continus®</intervention_name>
    <description>60 mg, capsule, once daily</description>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>liquid formulation and capsule, once daily</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with pain at least NRS &gt;4 due to painful diabetic polyneuropaty.

        Exclusion Criteria:

          -  Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl,
             hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound
             planned to be used during the anesthesia, or their excipients.

          -  non Caucasian or Hispanic.

          -  Concomitant painful disease.

          -  Life-long history of seizure disorder or epilepsy.

          -  Subjects with clinical relevant cardiac and vascular diseases.

          -  Subjects with impaired renal function

          -  Subjects with impaired hepatic function

          -  Female subjects who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKFE, Parcusstr. 8, 55116 Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator 3</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator 1</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator 2</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator 4</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <last_update_submitted>August 19, 2010</last_update_submitted>
  <last_update_submitted_qc>August 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Grünenthal GmbH</name_title>
    <organization>Grünenthal GmbH</organization>
  </responsible_party>
  <keyword>analgesic</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>chronic neuropathic pain</keyword>
  <keyword>painful polyneuropathy caused by diabetes mellitus type I or II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

